Response to induction chemotherapy and surgery in non-organ confined bladder cancer: A single institution experience

European Journal of Surgical Oncology

Volumn 39, Issue 4, 2013, Pages 365-371

  Meijer, R P ^a,b   Nieuwenhuijzen, J A ^c   Meinhardt, W ^a   Bex, A ^a   Van Der Poel, H G ^a   Van Rhijn, B W ^a   Kerst, J M ^a   Bergman, A M ^a   Van Werkhoven, E ^a   Horenblas, S ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bladder; Cancer; Cystectomy; Induction chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; CYSTECTOMY; FEMALE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYSTECTOMY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84875226903     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2013.01.003     Document Type: Article

References (29)

1. M.A. Ghoneim, M.M. el-Mekresh, M.A. el-Baz, I.A. el-Attar, and A. Ashamallah Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases J Urol 158 1997 393 399
2. G. Dalbagni, E. Genega, and M. Hashibe Cystectomy for bladder cancer: a contemporary series J Urol 165 2001 1111 1116
3. S. Madersbacher, W. Hochreiter, and F. Burkhard Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy J Clin Oncol 21 2003 690 696
4. J.P. Stein, G. Lieskovsky, and R. Cote Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 19 2001 666 675
5. H.W. Herr, and S.M. Donat Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy J Urol 165 2001 62 64 discussion 4
6. R.R. de Vries, J.A. Nieuwenhuijzen, W. Meinhardt, E.M. Bais, and S. Horenblas Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only Eur J Surg Oncol 35 2009 352 355
7. N.B. Dhar, E.A. Klein, A.M. Reuther, G.N. Thalmann, S. Madersbacher, and U.E. Studer Outcome after radical cystectomy with limited or extended pelvic lymph node dissection J Urol 179 2008 873 878 discussion 8
8. E. Winquist, T.S. Kirchner, R. Segal, J. Chin, and H. Lukka Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis J Urol 171 2004 561 569
9. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists Lancet 354 1999 533 540
10. A. Sherif, E. Rintala, and O. Mestad Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer-Nordic cystectomy trial 2 Scand J Urol Nephrol 36 2002 419 425
11. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration Eur Urol 48 2005 202 205 [discussion 5-6]
12. R.R. Hall Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer Proc Am Soc Clin Oncol 21 2002 (abstr 710)
13. G. Griffiths, R. Hall, R. Sylvester, D. Raghavan, and M.K. Parmar International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial J Clin Oncol 29 2011 2171 2177
14. C. Blick, P. Hall, and T. Pwint Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder Cancer 118 2012 3920 3927
15. S. Teramukai, H. Nishiyama, Y. Matsui, O. Ogawa, and M. Fukushima Evaluation for surrogacy of end points by using data from observational studies: tumor downstaging for evaluating neoadjuvant chemotherapy in invasive bladder cancer Clin Cancer Res 12 2006 139 143
16. T.A. Splinter, M. Pavone-Macaluso, and D. Jacqmin A European Organization for Research and Treatment of Cancer-Genitourinary Group phase 2 study of chemotherapy in stage T3-4N0-XM0 transitional cell cancer of the bladder: evaluation of clinical response J Urol 148 1992 1793 1796
17. R. Millikan, C. Dinney, and D. Swanson Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC J Clin Oncol 19 2001 4005 4013
18. C.N. Sternberg, V. Pansadoro, and F. Calabro Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 97 2003 1644 1652
19. R. Rosenblatt, A. Sherif, and E. Rintala Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer Eur Urol 61 2012 1229 1238
20. V. Sundararajan, T. Henderson, C. Perry, A. Muggivan, H. Quan, and W.A. Ghali New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality J Clin Epidemiol 57 2004 1288 1294
21. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
22. D.H. Sobin, M. Gospodarowicz, and C. Wittekind TNM classification of malignant tumours 7th ed. 2010 Wiley-Blackwell
23. M.D. Galsky, N.M. Hahn, and J. Rosenberg A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy Lancet Oncol 12 2011 211 214
24. J.A. Nieuwenhuijzen, A. Bex, and W. Meinhardt Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer J Urol 174 2005 80 85
25. H.W. Herr Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer Eur Urol 54 2008 126 132
26. A.S. Kibel, F. Dehdashti, and M.D. Katz Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma J Clin Oncol 27 2009 4314 4320
27. S. Harkirat, S. Anand, and M. Jacob Forced diuresis and dual-phase F-fluorodeoxyglucose-PET/CT scan for restaging of urinary bladder cancers Indian J Radiol Imaging 20 2010 13 19
28. S. Yoshida, F. Koga, and S. Kawakami Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer Urology 75 2010 387 391
29. L.S. Mertens, R.P. Meijer, and J.M. Kerst Carboplatin based induction chemotherapy for nonorgan confined bladder cancer-a reasonable alternative for cisplatin unfit patients? J Urol 188 2012 1108 1113